| Autor: |
Zheng DONG, Jian-hui QIAO, Chang-lin YU, Qi-yun SUN, Kai-xun HU, Hui-sheng AI, Xue-dong SUN, Bo YAO, Mei GUO |
| Jazyk: |
čínština |
| Rok vydání: |
2014 |
| Předmět: |
|
| Zdroj: |
Medical Journal of Chinese People's Liberation Army, Vol 39, Iss 1, Pp 48-51 (2014) |
| ISSN: |
0577-7402 |
| Popis: |
Objective To investigate the therapeutic effect of transplantation of non-myeloablative allogeneic hematopoietic stem cells in the treatment of myelodysplastic syndrome. Methods Fourteen patients with myelodysplastic syndrome received non-myeloablative allogeneic hematopoietic stem cells from HLA matched donors. The treatment regime consisted of cyclophosphamide, fludarabine, cyclosporine, anti-thymocyte globulin with or without busulfan. Graft-versus-hostdisease (GVHD) prophylaxis was performed with cyclosporine combined with mycophenolate mofetil. Results All the treatments were generally well tolerated and all patients received engraftment of the donor cells successfully. Engraftment was observed in 85.7% (12/14) patients with complete donor cells, and in 1 patient (7.1%) mixed chimerism was changed into full donor chimerism, and graft failure was 7.1% (1/14). Hematopoiesis (WBC recovered to more than 0.5×109/L during postoperative 9 day to 12 day and platelet recovered to more than 30×109/L during postoperative 11 day to 21 day) was recovered. The incidence of acute GVHD (gradeⅡ) was 7.1% (1/14) and no chronic GVHD was found. Interstitial pneumonia (IP) was not found in these fourteen patients. Overall survival rate was 78.6% during the follow-up time from 36 months to 133 months. Conclusion Transplantation of nonmyeloablative allogeneic hematopoietic stem cell is safe and effective for the treatment of myelodysplastic syndrome. DOI: 10.11855/j.issn.0577-7402.2014.01.11 |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
